Shanghai Bio-Heart Biological Technology Co., Ltd. Class H (HK:2185)
:2185
Want to see HK:2185 full AI Analyst Report?
Top Page
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
(2185)
Select Model
Select Model
Rating:45Neutral
Price Target:
HK$3.50
▼(-38.70% Downside)
Action:Reiterated
Date:05/05/26
The score is held back primarily by persistent operating losses and negative free cash flow despite the 2025 revenue rebound. Technicals are mixed with the stock still below key longer-term averages, and valuation is constrained by negative earnings and no stated dividend support. The main positive is low leverage, which helps near-term financial flexibility.
Positive Factors
Low leverage / balance sheet strength
Very low leverage provides durable financial flexibility for a development-stage biotech. With minimal debt the company can sustain R&D and commercialization timelines longer without immediate solvency pressure, improving its ability to raise capital on better terms and absorb operating losses while pursuing product development.
Negative Factors
Persistent unprofitability
Negative gross profit and sizable operating losses indicate the core business is not yet generating sustainable margins. Continued unprofitability erodes equity, limits reinvestment capacity, and means the company must demonstrate multi-quarter profit improvements to convert early revenue gains into durable shareholder value.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / balance sheet strength
Very low leverage provides durable financial flexibility for a development-stage biotech. With minimal debt the company can sustain R&D and commercialization timelines longer without immediate solvency pressure, improving its ability to raise capital on better terms and absorb operating losses while pursuing product development.
Read all positive factors
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H (2185) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$851.96M
Dividend YieldN/A
Average Volume (3M)2.14M
Price to Earnings (P/E)―
Beta (1Y)1.65
Revenue GrowthN/A
EPS Growth20.16%
CountryHK
Employees63
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.29
Shares Outstanding235,703,410
10 Day Avg. Volume3,698,147
30 Day Avg. Volume2,141,365
Financial Highlights & Ratios
PEG Ratio0.83
Price to Book (P/B)2.91
Price to Sales (P/S)28.92
P/FCF Ratio-17.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)HK$2.07B
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Shanghai Bio-heart Biological Technology Co., Ltd. operates as an interventional cardiovascular device company in the People's Republic of China. The company focuses on the provision of bioresorbable scaffolds (BRS) and renal denervation (RDN) the...
How the Company Makes Money
Publicly verifiable, company-specific details describing Shanghai Bio-Heart Biological Technology Co., Ltd.’s revenue model (e.g., disclosed primary revenue streams, named products generating sales, licensing terms, manufacturing/service income, o...
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
68
Positive
Cash Flow
17
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 43.77M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -157.81K | 0.00 | -23.60M | -24.25M | 0.00 |
| EBITDA | -52.13M | -44.54M | -148.21M | -237.34M | -400.88M |
| Net Income | -68.24M | -87.94M | -194.36M | -237.50M | -361.45M |
Balance Sheet | |||||
| Total Assets | 832.83M | 733.78M | 817.90M | 981.52M | 1.11B |
| Cash, Cash Equivalents and Short-Term Investments | 248.63M | 202.39M | 369.44M | 451.32M | 708.53M |
| Total Debt | 12.73M | 8.28M | 1.76M | 18.11M | 22.45M |
| Total Liabilities | 220.47M | 53.24M | 44.04M | 66.47M | 80.04M |
| Stockholders Equity | 435.00M | 660.47M | 748.41M | 883.21M | 995.69M |
Cash Flow | |||||
| Free Cash Flow | -72.91M | -166.69M | -66.74M | -170.65M | -147.28M |
| Operating Cash Flow | -65.48M | -119.55M | -49.03M | -140.62M | -105.45M |
| Investing Cash Flow | -39.78M | -46.03M | -28.86M | -100.69M | -33.73M |
| Financing Cash Flow | -1.74M | -2.44M | -5.82M | -35.18M | 383.68M |
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H Technical Analysis
Negative
5.71
Price Trends
4.30
Negative
5.00
Negative
5.97
Negative
Market Momentum
-0.15
Positive
34.07
Neutral
9.59
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2185, the sentiment is Negative. The current price of 5.71 is above the 20-day moving average (MA) of 4.19, above the 50-day MA of 4.30, and below the 200-day MA of 5.97, indicating a bearish trend. The MACD of -0.15 indicates Positive momentum. The RSI at 34.07 is Neutral, neither overbought nor oversold. The STOCH value of 9.59 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2185.
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | HK$4.36B | 2.00 | 2.04% | ― | 1117.02% | ― | |
54 Neutral | HK$3.38B | -16.22 | -14.53% | ― | -32.12% | -393.23% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$1.76B | -2.75 | -39.41% | ― | ― | 39.48% | |
47 Neutral | HK$1.47B | -4.01 | -12.64% | ― | -53.85% | 12.23% | |
45 Neutral | HK$851.96M | -7.27 | -15.19% | ― | ― | 20.16% | |
41 Neutral | HK$518.70M | -3.95 | 293.08% | ― | ― | -25.79% |
* Healthcare Sector Average
HK:2185
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
3.50
0.94
36.72%
HK:6998
Genor Biopharma Holdings Limited
2.17
-0.50
-18.73%
HK:1875
TOT BIOPHARM International Co. Ltd.
4.37
2.54
138.80%
HK:6622
Zhaoke Ophthalmology Ltd.
2.67
0.25
10.33%
HK:6978
Immunotech Biopharm Ltd
0.84
-2.14
-71.81%
HK:2511
Hightide Therapeutics Inc
3.45
0.60
21.05%
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H Corporate Events
Shanghai Bio-Heart Wins Vietnam Approval for Iberis Renal Denervation System
May 11, 2026
Shanghai Bio-Heart’s subsidiary AngioCare has secured registration of its Iberis multi-electrode renal artery radiofrequency ablation catheter system in Vietnam, expanding the device’s international footprint. The system, developed for...
Shanghai Bio-Heart Narrows Loss as Iberis RDN Launch Drives First Revenue
Mar 26, 2026
Shanghai Bio-Heart Biological Technology reported its first full year of revenue, booking RMB44.9 million in 2025 from the global launch of its Iberis RDN system for resistant hypertension, including the first commercial procedure in Europe and pr...
Shanghai Bio-Heart Secures Thailand Registration for Iberis Renal Denervation System
Mar 17, 2026
Shanghai Bio-Heart Biological Technology, through its subsidiary Shanghai AngioCare Medical Technology, has completed registration of its Iberis Multi-Electrode Renal Artery Radiofrequency Ablation Catheter System in Thailand, with support from pa...
Shanghai Bio-Heart Schedules Board Meeting to Approve 2025 Results and Consider Final Dividend
Mar 16, 2026
Shanghai Bio-Heart Biological Technology Co., Ltd., a Hong Kong-listed biotech firm based in Shanghai, has scheduled a board meeting for March 26, 2026, to review and approve its annual results for the year ended December 31, 2025. The board will ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.